About Ysios Capital
Ysios Capital is a venture capital firm founded in 2007. It is primarily based out of Barcelona, Spain. As of Sep 2026, Ysios Capital has invested in 44 companies. It primarily invests in Series A round in Spain based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series C round of Anaconda Biomed Overall, Ysios Capital portfolio has seen 5 IPOs and 11 acquisitions including key companies like CVRx, Neurona Therapeutics and Aura Biosciences. A lot of funds co-invest with Ysios Capital, with names like Sectoral sharing a substantial percentage of its portfolio. Ysios Capital has team of 12 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Ysios Capital's List of Top Investments
Ysios Capital has a portfolio of 44 companies. Their most notable investments are in Minoryx and LAVA therapeutics.Their portfolio spans across Spain, United States, Netherlands and 6 more locations. They have invested in Life Sciences, High Tech, HealthTech and 5 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Ysios Capital:1. CVRx
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
Key facts about CVRx
- Founded Year: 2001
- Location: Minneapolis (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $394M
- Employee Count: 262 as on Aug 31, 2026
- Investors: Gilde Healthcare, Piper Jaffray and 21 Others
- Latest Funding Round: Series F, Jul 07, 2020, $*****
- Highlight: Public
_1578644256370.png?format=webp&height=120&width=120){kind=logo}
Developer of antibody-drug-conjugates for cancer treatment. It offers a lead product TGW101 that targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors. It also offersolid-tumor-targeted ADCs as well as radiopharmaceuticals including a HER2-targeted radioimmunotherapeutic.
Key facts about Tagworks Pharmaceuticals
- Founded Year: 2011
- Location: Nijmegen (Netherlands)
- Stage: Series A
- Total Funding till date: $65M
- Employee Count: 45 as on Aug 31, 2026
- Investors: Gilde Healthcare, Novartis Venture Fund and 7 Others
- Latest Funding Round: Series A, Jun 22, 2023, $*****
- Highlight: Editors' Pick
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Key facts about Neurona Therapeutics
- Founded Year: 2008
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $418M
- Employee Count: 120 as on Aug 31, 2026
- Investors: Fidelity Investments, Topspin Fund and 15 Others
- Latest Funding Round: Series E, Mar 28, 2025, $*****
- Highlight: Acquired
Provider of therapies to target and destroy cancer cells. Its lead candidate is for the treatment of ocular (uveal) melanoma. It consists of a viral-like particle conjugated to an infra-red activated small molecule. It binds selectively to cancer cells in the eye and upon activation with an ophthalmic laser, the small molecule selectively destroys the membrane of cancer cells, killing them without damaging the overlying retina.
Key facts about Aura Biosciences
- Founded Year: 2007
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $215M
- Employee Count: 128 as on Aug 31, 2026
- Investors: Advent Life Sciences, Lundbeck Foundation and 20 Others
- Latest Funding Round: Series D, Mar 22, 2021, $*****
- Highlight: Public
5. CorWave
Developer of implantable heart assist pumps for advanced heart failure. These medical devices utilize wave membrane technology to provide pulsatile blood flow for patients suffering from cardiac conditions. The technology functions as a left ventricular assist device to support heart function.
Key facts about CorWave
- Founded Year: 2012
- Location: Clichy (France)
- Annual Revenue: €10M - €50M as on Dec 31, 2023
- Stage: Series C
- Total Funding till date: $92.8M
- Employee Count: 122 as on Aug 31, 2026
- Investors: Exor, Novo Holdings and 13 Others
- Latest Funding Round: Series C, Jun 20, 2023, $*****
- Highlight: Editors' Pick
Ysios Capital's Year-on-Year Investment Trends
Ysios Capital has invested in 44 companies over the last 19 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Sep 2026, it has made 3 investments in this year. Its most recent first time investment was in REPRONOVO and most recent follow-on round was in Anaconda Biomed.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 3 | 3 |
2025 | 1 | 2 | 3 |
2024 | 3 | 2 | 5 |
2023 | 2 | 2 | 4 |
2022 | 1 | 4 | 5 |
2021 | 4 | 2 | 6 |
2020 | 5 | 2 | 7 |
2019 | 0 | 6 | 6 |
2018 | 2 | 2 | 4 |
2017 | 3 | 3 | 6 |
Ysios Capital's Investments by Stage
Ysios Capital has made 19 investments in Series A stage with an average round size of $28M, 9 investments in Series B stage with an average round size of $55.1M and 6 investments in Series C stage with an average round size of $61.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 19 |
Series B | 9 |
Series C | 6 |
Series D | 2 |
Series F | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Ysios Capital's Investments by Sector
Ysios Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 42 Tech companies, 35 Enterprise (B2B) companies, 9 Software companies and at least 8 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 38 |
High Tech | 9 |
Enterprise Applications | 3 |
HealthTech | 3 |
Sustainability Tech | 3 |
Others | 7 |
Note: We have considered here, only first round of investments
Ysios Capital's Investments by Geography
Ysios Capital has made most investments in Spain (11), followed by United States where it has made 10 investments.Country | No. of Investments |
|---|---|
Spain | 11 |
United States | 10 |
Netherlands | 5 |
Switzerland | 5 |
Denmark | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
Ysios Capital's recent investments
Ysios Capital has made 3 investments in 2026 so far. Anaconda Biomed and Ona Therapeutics are the latest among them.Here are the most recent investments by Ysios Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 23, 2026 | Spain | Series C | 1256 | [+3] | |
Jun 04, 2026 | Spain | Series B | 2189 | ||
Apr 14, 2026 | Denmark | Series C | 9703 | [+15] | |
Oct 09, 2025 | Spain | Series A | 9662 | [+3] | |
Jun 11, 2025 | Spain | Series B | 7412 | [+7] |
IPOs and Publicly Listed companies in Ysios Capital's Portfolio
5 of Ysios Capital's portfolio companies have become public. Mineralys Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2023 at marketcap of $625M and Aura Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $398M.Here are Ysios Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 10, 2023 | Jun 01, 2022 | Series B | 9145 | |
Oct 29, 2021 | Mar 05, 2015 | Series B | 6250 | |
Jun 30, 2021 | Jul 15, 2013 | Series F | 1582 | |
Oct 29, 2020 | Oct 26, 2018 | Series C | 6883 | |
Jul 20, 2017 | Apr 22, 2014 | Series B | 4327 |
Acquired companies in Ysios Capital's Portfolio
11 companies from Ysios Capital's portfolio have been acquired. The most recent acquisition was Memo Therapeutics in Jul 2026 by Ipsen for $*****.Here are Ysios Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 01, 2026 | May 07, 2024 | Series C | 3667 | |
Apr 21, 2026 | Feb 06, 2024 | Series E | 4758 | |
Aug 04, 2025 | Sep 17, 2020 | Series C | 1987 | |
Mar 19, 2024 | - | - | 7198 | |
Nov 22, 2021 | Sep 08, 2015 | Series C | 1422 |
Team profile of Ysios Capital
Ysios Capital has a team of 12 members including 5 Partners and 2 Venture Partners located in Spain, France and 1 more location. Ysios Capital's team does not sit on the board of any company as of now.Here is a list of top team members in Ysios Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Bern | - | - | |
Partner | Palma De Mallorca | - | - | |
Partner | Paris | - | - | |
Partner | Barcelona | - | ||
Partner | Barcelona | - | - | |
Partner | Spain | - | - | |
Partner | Barcelona | - | - | |
Venture Partner | Barcelona | - | ||
Venture Partner | - | - | - |
Co-investors of Ysios Capital
Over the past 19 years, 315 investors have co-invested in Ysios Capital's portfolio companies. This includes funds and angels.
- Invested before Ysios Capital: Europa, Novo Holdings and 93 others have invested in rounds before Ysios Capital. There are 4 companies where Europa has invested before Ysios Capital and 4 companies where Novo Holdings has invested before Ysios Capital.
- Top Co-investors of Ysios Capital: 96 investors entered a company along with Ysios Capital. These include investors like Sectoral (4 companies).
- Invested after Ysios Capital: A total of 124 investors have invested in Ysios Capital's portfolio after their investments. Top Investors include EIC Fund (6 companies), Europa (6 companies) and Gilde Healthcare (4 companies).
Recent News related to Ysios Capital
•
Anaconda Biomed Secures $56 Million to Advance Thrombectomy Portfolio and ATHENA Pivotal TrialG-MedTech•Sep 25, 2026•Anaconda Biomed, Ysios Capital
•
Ysios Capital announces a new divestment following the acquisition of Memo Therapeutics by IpsenWebcapitalriesgo•Jul 02, 2026•Ysios Capital, Memo Therapeutics
•
Ona Therapeutics Secures 74 Million Euros to Advance Oncology Drug DevelopmentExpansion•Jun 04, 2026•Ona Therapeutics, Columbus Venture Partners, Merieux Equity Partners, Cuatrecasas and 6 others
•
•
Ysios Capital participates in Adcendo's $75M Series C roundWebcapitalriesgo•Apr 15, 2026•Ysios Capital
•
Ysios Capital launches InceptionBio, a €100 M fund to promote new biotechnologiesPharmatech industria farmaceutica•Apr 01, 2026•Ysios Capital
•
Spanish Investors Increasingly Backing AI, Climate Tech Equity DealsCrowdfund Insider•Oct 26, 2025•Kibo Ventures, Ysios Capital, CB Insights
•
ReproNovo Secures $65 Million in Series A FundingMoneycab•May 23, 2025•REPRONOVO, Jeito, AXA Investment Managers, M Ventures and 2 others
•
Reproductive health startup raises $65M for infertility drugsBioPharmaDive•May 22, 2025•REPRONOVO, Jeito, AXA Investment Managers, M Ventures and 2 others
•
ReproNovo Raises $65 Million Series A FinancingWebDisclosure•May 21, 2025•REPRONOVO, Jeito, AXA Investment Managers, M Ventures and 2 others
